Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy

D. R. Riggs, W. F. Tarry, J. I. DeHaven, J. Sosnowski, D. L. Lamm

    Research output: Contribution to journalArticle

    23 Citations (Scopus)

    Abstract

    BCG immunotherapy is very effective in the treatment of superficial transitional cell carcinoma of the bladder, but its significant toxicity may limit its use in some patients. In an effort to find less toxic and potentially more effective treatments we investigated the possible immunotherapeutic potential of combinations of Alpha Interferon (1000 IU) and Gamma Interferon (500 IU) with bacillus Calmette Guerin (BCG) (107 cfu), Interleukin-2 (4000 IU), and Keyhole Limpet Hemocyanin (50 μg.) in the MBT2 murine bladder cancer model. Significant reductions (p <0.05) in tumor incidence relative to the saline control, 83%, Day 35) was observed in groups receiving alpha interferon (42%), Keyhole limpet hemocyanin (42%), interleukin-2 (25%), alpha interferon+Keyhole limpet hemocyanin (17%), alpha interferon+interleukin-2 (33%), gamma interferon+BCG (42%), and gamma interferon+interleukin-2 (17%). All treatment groups with the exception of the group receiving gamma interferon had significantly reduced tumor volume (p <0.05) relative to the saline control. Combination treatment groups were significantly more effective than single agent treatments (p = 0.0057). The exhibited anti-tumor effect of these immunotherapeutic agents alone and in combination suggest that they may prove to be effective forms of immunotherapy for transitional cell carcinoma of the bladder.

    Original languageEnglish (US)
    Pages (from-to)212-214
    Number of pages3
    JournalJournal of Urology
    Volume147
    Issue number1
    StatePublished - 1992

    Fingerprint

    Transitional Cell Carcinoma
    Interferon-alpha
    Immunotherapy
    Interferon-gamma
    Urinary Bladder
    Interleukin-2
    Mycobacterium bovis
    Interleukin-17
    Therapeutics
    Poisons
    Tumor Burden
    Urinary Bladder Neoplasms
    Neoplasms
    Incidence
    keyhole-limpet hemocyanin

    Keywords

    • BCG vaccine
    • bladder neoplasms, immunotherapy, adoptive

    ASJC Scopus subject areas

    • Urology

    Cite this

    Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. / Riggs, D. R.; Tarry, W. F.; DeHaven, J. I.; Sosnowski, J.; Lamm, D. L.

    In: Journal of Urology, Vol. 147, No. 1, 1992, p. 212-214.

    Research output: Contribution to journalArticle

    Riggs, D. R. ; Tarry, W. F. ; DeHaven, J. I. ; Sosnowski, J. ; Lamm, D. L. / Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. In: Journal of Urology. 1992 ; Vol. 147, No. 1. pp. 212-214.
    @article{14d4f14b2b9f460f843714c9532c1ad5,
    title = "Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy",
    abstract = "BCG immunotherapy is very effective in the treatment of superficial transitional cell carcinoma of the bladder, but its significant toxicity may limit its use in some patients. In an effort to find less toxic and potentially more effective treatments we investigated the possible immunotherapeutic potential of combinations of Alpha Interferon (1000 IU) and Gamma Interferon (500 IU) with bacillus Calmette Guerin (BCG) (107 cfu), Interleukin-2 (4000 IU), and Keyhole Limpet Hemocyanin (50 μg.) in the MBT2 murine bladder cancer model. Significant reductions (p <0.05) in tumor incidence relative to the saline control, 83{\%}, Day 35) was observed in groups receiving alpha interferon (42{\%}), Keyhole limpet hemocyanin (42{\%}), interleukin-2 (25{\%}), alpha interferon+Keyhole limpet hemocyanin (17{\%}), alpha interferon+interleukin-2 (33{\%}), gamma interferon+BCG (42{\%}), and gamma interferon+interleukin-2 (17{\%}). All treatment groups with the exception of the group receiving gamma interferon had significantly reduced tumor volume (p <0.05) relative to the saline control. Combination treatment groups were significantly more effective than single agent treatments (p = 0.0057). The exhibited anti-tumor effect of these immunotherapeutic agents alone and in combination suggest that they may prove to be effective forms of immunotherapy for transitional cell carcinoma of the bladder.",
    keywords = "BCG vaccine, bladder neoplasms, immunotherapy, adoptive",
    author = "Riggs, {D. R.} and Tarry, {W. F.} and DeHaven, {J. I.} and J. Sosnowski and Lamm, {D. L.}",
    year = "1992",
    language = "English (US)",
    volume = "147",
    pages = "212--214",
    journal = "Journal of Urology",
    issn = "0022-5347",
    publisher = "Elsevier Inc.",
    number = "1",

    }

    TY - JOUR

    T1 - Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy

    AU - Riggs, D. R.

    AU - Tarry, W. F.

    AU - DeHaven, J. I.

    AU - Sosnowski, J.

    AU - Lamm, D. L.

    PY - 1992

    Y1 - 1992

    N2 - BCG immunotherapy is very effective in the treatment of superficial transitional cell carcinoma of the bladder, but its significant toxicity may limit its use in some patients. In an effort to find less toxic and potentially more effective treatments we investigated the possible immunotherapeutic potential of combinations of Alpha Interferon (1000 IU) and Gamma Interferon (500 IU) with bacillus Calmette Guerin (BCG) (107 cfu), Interleukin-2 (4000 IU), and Keyhole Limpet Hemocyanin (50 μg.) in the MBT2 murine bladder cancer model. Significant reductions (p <0.05) in tumor incidence relative to the saline control, 83%, Day 35) was observed in groups receiving alpha interferon (42%), Keyhole limpet hemocyanin (42%), interleukin-2 (25%), alpha interferon+Keyhole limpet hemocyanin (17%), alpha interferon+interleukin-2 (33%), gamma interferon+BCG (42%), and gamma interferon+interleukin-2 (17%). All treatment groups with the exception of the group receiving gamma interferon had significantly reduced tumor volume (p <0.05) relative to the saline control. Combination treatment groups were significantly more effective than single agent treatments (p = 0.0057). The exhibited anti-tumor effect of these immunotherapeutic agents alone and in combination suggest that they may prove to be effective forms of immunotherapy for transitional cell carcinoma of the bladder.

    AB - BCG immunotherapy is very effective in the treatment of superficial transitional cell carcinoma of the bladder, but its significant toxicity may limit its use in some patients. In an effort to find less toxic and potentially more effective treatments we investigated the possible immunotherapeutic potential of combinations of Alpha Interferon (1000 IU) and Gamma Interferon (500 IU) with bacillus Calmette Guerin (BCG) (107 cfu), Interleukin-2 (4000 IU), and Keyhole Limpet Hemocyanin (50 μg.) in the MBT2 murine bladder cancer model. Significant reductions (p <0.05) in tumor incidence relative to the saline control, 83%, Day 35) was observed in groups receiving alpha interferon (42%), Keyhole limpet hemocyanin (42%), interleukin-2 (25%), alpha interferon+Keyhole limpet hemocyanin (17%), alpha interferon+interleukin-2 (33%), gamma interferon+BCG (42%), and gamma interferon+interleukin-2 (17%). All treatment groups with the exception of the group receiving gamma interferon had significantly reduced tumor volume (p <0.05) relative to the saline control. Combination treatment groups were significantly more effective than single agent treatments (p = 0.0057). The exhibited anti-tumor effect of these immunotherapeutic agents alone and in combination suggest that they may prove to be effective forms of immunotherapy for transitional cell carcinoma of the bladder.

    KW - BCG vaccine

    KW - bladder neoplasms, immunotherapy, adoptive

    UR - http://www.scopus.com/inward/record.url?scp=0026542821&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0026542821&partnerID=8YFLogxK

    M3 - Article

    VL - 147

    SP - 212

    EP - 214

    JO - Journal of Urology

    JF - Journal of Urology

    SN - 0022-5347

    IS - 1

    ER -